Antipsychotic-evoked dopamine supersensitivity

@article{Servonnet2020AntipsychoticevokedDS,
  title={Antipsychotic-evoked dopamine supersensitivity},
  author={Alice Servonnet and Anne-No{\"e}l Samaha},
  journal={Neuropharmacology},
  year={2020},
  volume={163}
}
Dopamine D2 up-regulation in psychosis patients after antipsychotic drug treatment.
TLDR
Further research is needed to investigate whether antipsychotic medication causes neuroadaptations leading to a dopamine supersensitive state in humans, how long such hypersensitive states may last and what differences exist between high and low D2 affinity antipsychotics.
Recent Discussions on Dopamine Supersensitivity Psychosis: Eight Points to Consider When Diagnosing Treatment-Resistant Schizophrenia
TLDR
Clinicians speculate about the background of severe psychopathology in a given patient; to make diagnoses of treatment-resistant schizophrenia and dopamine supersensitivity psychosis; and plan antipsychotic medication regimens with the goal of achieving better long-term prognosis.
Individualizing tapering antipsychotic schemes considering D2 blockade dynamics
TLDR
In a viewpoint, the authors indicate that when reduction is appropriate, the concept of neuroadaptation should guide the rationale leading to adopting a slow, hyperbolic titration, and go in a different direction from the standard procedure of using fixed intervals, possibly increasing relapse risk.
Reduced erythrocyte membrane polyunsaturated fatty acid levels indicate diminished treatment response in patients with multi- versus first-episode schizophrenia
TLDR
Using targeted metabolomic approach, the potential mechanisms underlying abnormal fatty acid metabolism responsible for reduced treatment response in patients with multi-episode schizophrenia are revealed.
Influence of clinical and therapeutic indicators on the severity of neurocognitive deficits in patients with schizophrenia
TLDR
The severity of positive symptoms of schizophrenia was lower in patients with mild neurocognitive deficits and the obtained results on antipsychotics as a whole were obtained due to AAD.
Influence of clinical and therapeutic indicators on the severity of neurocognitive deficits in patients with schizophrenia
TLDR
The severity of positive symptoms of schizophrenia was lower in patients with mild neurocognitive deficits and the obtained results on antipsychotics as a whole were obtained due to AAD.
...
...

References

SHOWING 1-10 OF 180 REFERENCES
Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy
TLDR
Criteria for SP is proposed, which describe psychotic symptoms and co-occurring movement disorders more precisely, and 3 antipsychotic withdrawal syndromes are described, similar to those seen with other CNS drugs, and approaches to treat, potentially prevent, or temporarily manage SP are proposed.
“Breakthrough” Dopamine Supersensitivity during Ongoing Antipsychotic Treatment Leads to Treatment Failure over Time
TLDR
It is shown that during ongoing treatment with clinically relevant doses, haloperidol and olanzapine progressively lose their efficacy in suppressing amphetamine-induced locomotion and conditioned avoidance responding and is linked to an increase in D2 receptor number and sensitivity.
Can antipsychotic treatment contribute to drug addiction in schizophrenia?
  • A. Samaha
  • Psychology, Medicine
    Progress in Neuro-Psychopharmacology and Biological Psychiatry
  • 2014
Dynamic regulation of dopamine and serotonin responses to salient stimuli during chronic haloperidol treatment.
TLDR
In-vivo voltammetry showed that nucleus accumbens dopamine adaptations and their reversal were mediated by changes in extracellular dopamine release, which may be a functional substrate of antipsychotic action and failure respectively.
A dopaminergic mechanism of antipsychotic drug efficacy, failure, and failure reversal: the role of the dopamine transporter
TLDR
It is reported that antipsychotic efficacy in rat models declines in concert with extracellular striatal dopamine levels rather than insufficient dopamine D2 receptor occupancy, supporting the hypothesis that the dopamine transporter is a main target of antippsychotic drugs and predicting that dopamine transporter blockers may be an adjunct treatment to reverse antipsychotics treatment failure.
Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study
TLDR
It is demonstrated for the first time, using in vivo neuroreceptor imaging, that dopamine D2 receptor binding is increased after long-term treatment with antipsychotics in humans.
Prior haloperidol, but not olanzapine, exposure augments the pursuit of reward cues: implications for substance abuse in schizophrenia.
TLDR
It is suggested that HAL, but not an atypical like OLZ, modifies reward circuitry in ways that increase responsiveness to reward cues, which could help schizophrenic patients at risk for drug abuse or addiction.
Dopamine synthesis capacity in patients with treatment-resistant schizophrenia.
TLDR
In some patients with schizophrenia, antipsychotic treatment may be ineffective because they do not exhibit the elevation in dopamine synthesis capacity that is classically associated with the disorder; this may reflect a different underlying pathophysiology or a differential effect of antipsychotics.
...
...